Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab–bevacizumab resistance and worse survival in advanced hepatocarcinoma
A repeatable, easy, non-invasive blood test predicts response to immunotherapy in patients with HCC, both in terms of TTP and OS. CTLA4+ cell percentage increase in non-responders suggests a possible resistance mechanism which deserves attention as a druggable target.
Authors
- L. Gramantieri
- Cristian Bassi (ORCID: https://orcid.org/0000-0002-5823-709X)
- Eleonora Alimenti (ORCID: https://orcid.org/0000-0001-8733-0245)
- M. Negrini
- Francesco Tovoli (ORCID: https://orcid.org/0000-0002-8350-1155)
- Catia Giovannini (ORCID: https://orcid.org/0000-0003-1904-1577)
- Fabio Piscaglia (ORCID: https://orcid.org/0000-0001-8264-1845)
- Annapaola Montagner
- Mariangela Bruccoleri (ORCID: https://orcid.org/0000-0001-7400-4854)
- F. Suzzi
- Francesca Fornari (ORCID: https://orcid.org/0000-0002-4302-4411)
- Andrea Arleo (ORCID: https://orcid.org/0000-0002-3262-7268)
- Massimo Alberto Iavarone (ORCID: https://orcid.org/0000-0003-3493-6504)
Institutions
- University of Ferrara (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Azienda USL di Bologna (IT)
- University of Bologna (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104289
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Ministero della Salute
- Università di Bologna